Rivaroxaban - Bio-synectics
Alternative Names: BS-112Latest Information Update: 15 Feb 2024
At a glance
- Originator Bio-Synectics
- Class Amides; Anticoagulants; Antithrombotics; Cardiovascular therapies; Chlorinated hydrocarbons; Ketones; Morpholines; Oxazolidinones; Small molecules; Thiophenes
- Mechanism of Action Factor Xa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Deep vein thrombosis; Pulmonary embolism
Most Recent Events
- 15 Feb 2024 Phase I development is ongoing for Pulmonary-embolism and Deep-vein-thrombosis in South Korea (PO, Tablet) (Bio Synectics pipeline, February 2024)
- 28 Sep 2023 No recent reports of development identified for phase-I development in Deep-vein-thrombosis in South Korea (PO, Tablet)
- 28 Sep 2023 No recent reports of development identified for phase-I development in Pulmonary-embolism in South Korea (PO, Tablet)